Maxim Group analyst Jason McCarthy maintained a Hold rating on Cytori Therapeutics Inc (CYTX) today. The company’s shares opened today at $0.38, close to its 52-week low of $0.29.
McCarthy said:
“Cytori announced Class III approval for the consumables bundle associated with the company’s Japan, expanding its current commercial efforts in the country. The first consumable lots of the product already shipped in November.”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.3% and a 37.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Cytori Therapeutics Inc is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.40 and a one-year low of $0.29. Currently, Cytori Therapeutics Inc has an average volume of 587.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytori Therapeutics, Inc. is a late stage cell therapy company which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.
